17.08.2013 Views

2012 Program Booklet - MCD Biology - University of Colorado Boulder

2012 Program Booklet - MCD Biology - University of Colorado Boulder

2012 Program Booklet - MCD Biology - University of Colorado Boulder

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Jennifer Leeds, PhD<br />

Executive Director-­‐ Antibacterial Discovery<br />

Infectious Diseases Area<br />

Novartis Institute for BioMedical Research<br />

Title: Discovery and development <strong>of</strong> LFF571, a<br />

novel antibacterial for the treatment <strong>of</strong> C.<br />

difficile infection.<br />

Friday, October 12<br />

6.10-­‐6.55 pm<br />

JSCBB Butcher Auditorium<br />

Abstract:<br />

Antibiotics are among the most important advances in the history <strong>of</strong> modern medicine.<br />

Antibiotics transform deadly bacterial infections into curable diseases, and enable surgical and<br />

medical innovation in nearly every therapeutic area. However, the increasing use <strong>of</strong><br />

antibiotics has contributed to the rise in drug resistant and multi-­‐drug resistant pathogens<br />

both in the community and in the hospital setting. At the same time, the number <strong>of</strong> new<br />

agents to treat bacterial infections is diminishing, partly due to the difficulty in identifying ideal<br />

targets and chemical starting points as well as increasing challenges in treating patients with<br />

complex medical needs. New agents should be potent against organisms exhibiting clinically-­‐<br />

relevant drug resistant phenotypes. The discovery <strong>of</strong> new chemical entities targeting<br />

unexploited mechanisms <strong>of</strong> growth inhibition is one strategy to address this hurdle. This was<br />

the origin <strong>of</strong> the drug discovery program that led us to discover LFF571. LFF571 is a new<br />

chemical entity that is currently being evaluated for safety and efficacy in patients with<br />

Clostridium difficile infection. The discovery and early development program for this novel<br />

compound will be presented.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!